spacer
home > pmps > autumn 2017 > making the switch
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Making the Switch

The global pharmaceutical manufacturing sector revenue is estimated to increase to around $1,226 billion by 2018. To remain competitive in such a large market, these organisations must optimise processes to create low-expense products without compromising quality. The adoption of continuous manufacturing will offer the industry many benefits.

Pharma production is a well-established sector that provides high-quality and affordable medication to the population. However, manufacturers often rely on older processes rather than adapting to meet the growing needs of consumers.

Traditionally, batch manufacturing produces the majority of drugs sold worldwide – a method that isolates each process. Workers will handle the product at each stage, sending it to be tested in laboratories before the next step. While this works effectively, receiving the final item may take months. Companies are looking for new solutions to reduce costs, environmental impact and development time.

In the boom of Industry 4.0, many sectors, such as chemicals and gas, have implemented more advanced technology to optimise production. Integrated automation systems can streamline an assembly line to efficiently create medication and devices frequently, with little human interaction. Continuous manufacturing is an advancement that developers should utilise to reap the same benefits as these industries.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jonathan Wilkins is Marketing Director at EU Automation and is also one of the most prolific Industry 4.0 writers in the industrial automation sector. A professional brand advocate and commercial marketing strategist, he has been part of the company since its humble beginnings in 2009 and has over a decade of experience in marketing.
spacer
Jonathan Wilkins
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Phenomenex Introduces bioZen Series for Characterization of Biotherapeutics

Torrance, Calif. (April 16, 2018) – Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, introduces bioZen – a new series of LC solutions for bioseparations in pharmaceutical, biopharmaceutical and academic research. The series encompasses both proven and entirely new media spanning two particle platforms – core-shell and thermally modified fully porous – along with new biocompatible titanium hardware. The initial bioZen product line features seven chemistries for the UHPLC and HPLC characterization of biotherapeutics such as monoclonal antibodies, antibody-drug conjugates and biosimilars. The offering includes specific LC chemistries for the analysis of aggregates and total mAb, intact mass and fragments, peptide mapping and quantitation and glycan mapping.
More info >>

White Papers

Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials

Perceptive Informatics

Standardized assessment criteria are becoming increasingly important in obtaining valid outcomes in oncology clinical trials. While standardized criteria encourage a more uniform approach to assessing clinical trial data, they are often subject to the interpretation of the user. These differences in interpretation, while seemingly minor, can have a major impact on assessments. The most commonly used standardized criteria for lymphoma have been no exception. Differences such as minimum new lesion size, lymph node normalization size requirements, inclusion of extranodal lesions and assessment of organomegaly can have a profound effect on overall response. Additionally, heightened scrutiny of the assessment criteria used in a given protocol can lead to questions about a drug’s efficacy if not applied correctly according to regulators’ interpretation.
More info >>

 
Industry Events

PDA Universe of Pre-Filled Syringes and Injection Devices

8 October - 9 November 2018, Loews Royal Pacific, Orlando, FL

At the 2018 PDA Universe of Pre-filled Syringes and Injection Devices,industry and regulatory experts will share experiences, new developments, regulatory considerations, challenges, and industry trends and best practices. This is a must-attend event for all industry professionals involved in the development, manufacturing, testing, or marketing of pre-filled syringes and injection devices.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement